Oxford BioMedica

Oxford Biomedica is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.[2]

Oxford BioMedica plc
Public company
Traded asLSE: OXB
IndustryPharmaceutical industry
Founded1995
HeadquartersOxford
Key people
Lorenzo Tallarigo (Chairman)
John Dawson (CEO)
Revenue£94.1 million (2019)[1]
£(14.5) million (2019)[1]
£(16.1) million (2019)[1]
Websitewww.oxb.com

History

The company was established in 1995 as a spin out from Oxford University.[3] It was the subject of an initial public offering on the Alternative Investment Market in 1996.[4]

In 2018, Oxford Biomedica's gene therapy for Parkinson's disease became the subject of a commercialization deal with Axovant Sciences.[5]

In May 2019, the company announced an investment by Novo Holdings for a stake of 10.1% in Oxford Biomedica, totaling $55 million (USD) to develop its gene therapy technology.[6] The firm had already established collaborations with Sanofi, Novartis and other groups to provide lentiviral vector manufacturing.[7]

In November 2019, Microsoft announced a partnership with Oxford Biomedica to improve the next generation of cell and gene delivery technology using the cloud and machine learning, contributing large data sets for analysis via the Microsoft Azure intelligent cloud platform to develop in-silico models and novel algorithms to help provide long-term and curative treatments for a wide range of diseases.[8]

In December 2019, the company announced that it has extended its commercial supply agreement with Novartis for the manufacture of lentiviral vectors for the Novartis CAR-T portfolio including five lentiviral vectors for CAR-T products, which builds on the existing three-year commercial supply agreement signed by the parties in July 2017.[9]   

In April 2020, Oxford BioMedica announced that the company had joined a Consortium led by the Jenner Institute, Oxford University, to develop and manufacture a potential vaccine for COVID-19: ChAdOx1 nCov-19[10]. This is one of the many vaccine candidates currently in development globally, and is expected to be trialed with volunteers aged 18-55 in the Thames Valley area.[11]

gollark: I control the bees, fool.
gollark: Hmm, I should probably support labels actually.
gollark: No.
gollark: I have bridged some CC computers to Prometheus. None can escape.
gollark: What's it bridging?

References
  1. "Preliminary Results 2019". Oxford BioMedica. Retrieved 3 June 2020.
  2. "FTSE UK Index Series: Annual Review June 2020". 3 June 2020. Retrieved 3 June 2020.
  3. Hoover's | A D&B Company. Hoovers.com.
  4. Owen, Geoffrey; Hopkins, Michael M. (2016). Science, the State and the City: Britain's Struggle to Succeed in Biotechnology. Oxford University Press. p. 174. ISBN 978-0198728009.
  5. Cookson, Clive (6 June 2018). "Oxford BioMedica seals $842m Parkinson's therapy deal with Axovant". Retrieved 27 June 2018.
  6. Medical, Jonathan Smith-29/05/2019 1 min- (29 May 2019). "€60M Investment to Boost Oxford Biomedica's Gene and Cell Therapies". Labiotech.eu. Retrieved 13 March 2020.
  7. "Plenty of choice remains for buyers of gene therapy". Evaluate.com. 20 December 2019. Retrieved 26 March 2020.
  8. Rut, Andrew (28 October 2019). "Transforming the landscape". PharmaTimes. Retrieved 4 March 2020.
  9. "Oxford Biomedica extends lentiviral deal with Swiss giant". Phara Letter. 19 December 2019. Retrieved 3 June 2020.
  10. "Could the Oxford University/AstraZeneca COVID-19 Vaccine End the Pandemic?". 2 July 2020. Retrieved 25 June 2020.
  11. "Oxford Biomedica joins consortium for promising COVID-19 vaccine". Pharma Times. 8 April 2020. Retrieved 3 June 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.